Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
143 hedge funds and large institutions have $1.75B invested in Alder Biopharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 36 increasing their positions, 38 reducing their positions, and 31 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
65% more capital invested
Capital invested by funds: $1.06B → $1.75B (+$693M)
52% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 31
13% more funds holding
Funds holding: 127 → 143 (+16)
5% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 38
95% less call options, than puts
Call options by funds: $5.68M | Put options by funds: $115M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$47.6M |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
+$40.6M |
| 3 |
DKCM
Davidson Kempner Capital Management
New York
|
+$37.9M |
| 4 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$35.3M |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$35.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$121M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$80.8M |
| 3 |
SC
Samlyn Capital
New York
|
-$31.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$28M |
| 5 |
Goldman Sachs
New York
|
-$22.8M |
ALDR Hedge Fund Activity: Q3 2019 in Review
143 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q3 2019, worth a combined $1.75B — up 65% from $1.06B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new ALDR positions and 31 closed out — a net gain of 16 holders — while 36 added to existing stakes and 38 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $47.6M. The largest seller was Wellington Management Group, exiting entirely with an estimated $121M sold.
- 143 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q3 2019, up from 127 in Q2 2019.
- Funds reported $1.75B of Alder Biopharmaceuticals stock for Q3 2019, up 65% quarter-over-quarter.
- 47 funds opened new Alder Biopharmaceuticals positions in Q3 2019 and 31 closed out, a net change of +16 holders.
- The largest Alder Biopharmaceuticals buyer in Q3 2019 was Farallon Capital Management, an estimated $47.6M added.
- The largest Alder Biopharmaceuticals seller in Q3 2019 was Wellington Management Group, an estimated $121M sold.
Based on aggregated 13F filings for Q3 2019.